While combination estrogen/progestagen therapy decreases the risk of endometrial cancer compared with estrogen therapy alone, it causes a greater increase in breast cancer and, thus, a greater increase in total cancer incidence when used either continuously or cyclically, according to the latest findings from the Million Women Study.
While combination estrogen/progestagen therapy decreases the risk of endometrial cancer compared with estrogen therapy alone, it causes a greater increase in breast cancer and, thus, a greater increase in total cancer incidence when used either continuously or cyclically, according to the latest findings from the Million Women Study.
Researchers recruited over 700,000 postmenopausal women from the UK without previous cancer or hysterectomy and followed them for an average of 3.4 years. They found that compared with those who never used HT, the risk of endometrial cancer was reduced in women who last used a continuous combined HRT preparation (relative risk 0.71); increased in women who last used tibolone (RR 1.79), and in women who last used estrogen only (RR 1.45); and did not significantly change in women who last used a cyclic combined preparation (RR 1.05).
In addition, the researchers found that the adverse effects of tibolone and estrogen-only HRT were greatest in non-obese women and that the beneficial effects of combined HRT were greatest in obese women.
Million Women Study Collaborators. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2005;365:1543-1551.
Brinton LA, Lacey JV Jr, Trimble EL. Hormones and endometrial cancer-new data from the Million Women Study. Lancet. 2005;365:1517-1518.
Severe maternal morbidity linked to mental health risks post-delivery
April 26th 2024A recent study revealed that severe maternal morbidity during pregnancy increases the likelihood of mental health hospitalizations or emergency department visits up to 13 years post-delivery, emphasizing the need for mental health screening.
Read More
FDA approves updated label for Biktarvy against HIV-1
April 26th 2024Gilead Sciences has announced FDA approval of an updated Biktarvy label, showcasing safety and efficacy data from a phase 1b trial, positioning it as a pivotal treatment option for pregnant individuals with HIV-1 and suppressed viral load.
Read More
No link found between antenatal corticosteroids and child neurodevelopment
April 25th 2024A recent study found no link between antenatal corticosteroid administration and adverse neurodevelopmental outcomes in children aged 6 years or older, offering reassurance for late preterm delivery practices.
Read More